PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Upcoming Events

PEGS Boston
ELRIG Drug Discovery USA
ELRIG Cell and Gene Therapy 18.02.25
Biotechnology Show 13.02.26
NexGen Biomed 23.01.25
PFS & Injectable drug devices west coast
PFS & Injectable Drug Devices East Cost
AI in Drug Discovery
Bio Trinity
Anglo Nordic

Advertisement

A&M STABTEST: Fri 21 June 2024, 11:43
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025
Light Cast – 17.07.2025
QMB Innovation Centre

Delivering the Future: Overcoming Shipping Challenges in Cell and Gene Therapy 

The rise of cell and gene therapy (CGT) is revolutionising how we treat complex diseases, offering life-changing treatments for patients in need. However, with these innovations come significant logistical challenges. 

Ensuring these highly specialised therapies reach patients on time, without damage, is crucial. As the CGT market expands, logistics must keep pace to protect the integrity of these groundbreaking treatments. 

High-Stakes Medicine Meets Outdated Logistics
The CGT industry is growing rapidly, but the logistics supporting it have struggled to keep pace. CGT treatments are personalised, highly sensitive, and time-critical, making their durability and availability incredibly limited. Simply put, these treatments are some of the most expensive and delicate shipments moving around the world right now – and that means the standard supply chain playbook no longer applies. 

Reaching upwards of $4 million per dose, CGT offers life-altering potential at an incredibly high cost. Once manufactured, these therapies must be administered to patients within hours, and they often require ultra-low temperatures during transport. Should any of these treatments be lost, damaged, or delayed in transit, the manufacturing process would have to start over. For patients waiting to receive these therapies, that’s time that they may not survive. 

It’s no wonder the logistics behind this process are daunting. Not only do logistics teams face the possibility of losing millions of dollars in product, but they are responsible for delivering potentially life-saving treatments. The specific needs of these fragile therapies create a new set of issues that many companies don’t fully understand, and therefore, aren’t ready to support. 

The CGT Cold Chain Challenge 
One of the key issues in CGT shipping is outdated cold chain infrastructure. Traditional shipment tracking methods, such as barcode scanning, provide only a snapshot of the shipment’s location, leaving teams in the dark about the cargo’s real-time condition. Considering how incredibly time-sensitive CGT shipments are, this lack of visibility can be catastrophic.

The Bridge 28.01
Newcells 3 June 2024, 15:12
Aldevron: 16th January 2025
Richter: Wed 23 October 2024, 09:03
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025
Crown Bioscience 08.09.2025
Polypure hompage